BR0214944A - Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais - Google Patents

Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais

Info

Publication number
BR0214944A
BR0214944A BR0214944-3A BR0214944A BR0214944A BR 0214944 A BR0214944 A BR 0214944A BR 0214944 A BR0214944 A BR 0214944A BR 0214944 A BR0214944 A BR 0214944A
Authority
BR
Brazil
Prior art keywords
viral infections
treatment
acylcytosine
nucleosides
fluorocytidine
Prior art date
Application number
BR0214944-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Junxing Shi
Michael J Otto
Kyoichi A Watanabe
Original Assignee
Pharmasset Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd filed Critical Pharmasset Ltd
Publication of BR0214944A publication Critical patent/BR0214944A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0214944-3A 2001-12-14 2002-12-13 Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais BR0214944A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34155501P 2001-12-14 2001-12-14
PCT/US2002/040081 WO2003063771A2 (en) 2001-12-14 2002-12-13 N4-acylcytosine nucleosides for treatment of viral iinfections

Publications (1)

Publication Number Publication Date
BR0214944A true BR0214944A (pt) 2005-06-07

Family

ID=23338072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214944-3A BR0214944A (pt) 2001-12-14 2002-12-13 Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais

Country Status (10)

Country Link
US (6) US7105527B2 (https=)
EP (1) EP1569652A4 (https=)
JP (1) JP2005519916A (https=)
KR (1) KR100978904B1 (https=)
CN (1) CN100560073C (https=)
AU (2) AU2002365234B2 (https=)
BR (1) BR0214944A (https=)
CA (1) CA2470255C (https=)
MX (1) MXPA04005779A (https=)
WO (2) WO2003063771A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
EP1964569A3 (en) 2000-04-13 2009-07-22 Pharmasset, Inc. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of viral infections
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
EP1569652A4 (en) * 2001-12-14 2008-07-02 Pharmasset Inc NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL374781A1 (en) * 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP2006507235A (ja) 2002-08-01 2006-03-02 フアーマセツト・インコーポレイテツド フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
HUE033832T2 (en) * 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
CA2425031A1 (en) * 2003-04-01 2004-10-01 Smithkline Beecham Corporation Pharmaceutical compositions
EP2345657A1 (en) * 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2005097618A2 (en) * 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Sciences, Inc. Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
WO2006044968A2 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US7968703B2 (en) * 2005-03-07 2011-06-28 Shire Canada Inc. Process and methods for the preparation of optically active cis-2-hydroxymethyl-4- (cytosin-1'-yl)-1,3-oxathiolane or pharmaceutically acceptable salts thereof
EP1976382B1 (en) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN103242400B (zh) * 2012-02-08 2016-06-08 河南师范大学 具有抗hiv活性的5-取代嘧啶核苷-噻唑啉酮杂化体及其制备方法
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
DK3512863T3 (da) 2016-09-07 2022-03-07 Atea Pharmaceuticals Inc 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
CN115477679A (zh) 2017-02-01 2022-12-16 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US13660A (en) * 1855-10-09 Improvements
US3309359A (en) * 1965-10-22 1967-03-14 Hoffmann La Roche N-mono-acyl-5-fluorocytosine derivatives and process
NL8202626A (nl) 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA886890B (en) * 1987-10-09 1989-05-30 Hoffmann La Roche Novel dideoxycytidine derivatives
US6350753B1 (en) * 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
NL8901258A (nl) 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
DD293498A5 (de) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
JPH05310777A (ja) 1992-05-14 1993-11-22 Yoshitomi Pharmaceut Ind Ltd ２’−デオキシ−２’−メチリデンシチジン化合物
TW254946B (https=) * 1992-12-18 1995-08-21 Hoffmann La Roche
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
GB9525606D0 (en) 1995-12-14 1996-02-14 Iaf Biochem Int Method and compositions for the synthesis of dioxolane nucleosides with › - configuration
AU4988697A (en) * 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
WO1999026958A1 (en) * 1997-11-25 1999-06-03 Protarga, Inc. Nucleoside analog compositions and uses thereof
KR100719606B1 (ko) * 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
AU1201502A (en) * 2000-10-13 2002-04-22 Shire Biochem Inc Dioxolane analogs for improved inter-cellular delivery
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
EP1569652A4 (en) * 2001-12-14 2008-07-02 Pharmasset Inc NUCLEOSIDES N SP 4 / SP-ACYLCYTOSINES FOR THE TREATMENT OF VIRAL INFECTIONS

Also Published As

Publication number Publication date
MXPA04005779A (es) 2005-05-16
WO2003051306A2 (en) 2003-06-26
EP1569652A4 (en) 2008-07-02
CA2470255A1 (en) 2003-08-07
WO2003063771A3 (en) 2005-07-07
US20070078080A1 (en) 2007-04-05
US8114997B2 (en) 2012-02-14
USRE42015E1 (en) 2010-12-28
WO2003051306A3 (en) 2003-12-18
US20030176319A1 (en) 2003-09-18
CN1617726A (zh) 2005-05-18
CA2470255C (en) 2012-01-17
AU2002365234B2 (en) 2009-01-29
WO2003063771A2 (en) 2003-08-07
US6908924B2 (en) 2005-06-21
JP2005519916A (ja) 2005-07-07
EP1569652A2 (en) 2005-09-07
US20040214844A1 (en) 2004-10-28
US7105527B2 (en) 2006-09-12
AU2002364730A8 (en) 2003-06-30
KR100978904B1 (ko) 2010-08-31
AU2002364730A1 (en) 2003-06-30
US20120202766A1 (en) 2012-08-09
CN100560073C (zh) 2009-11-18
US20090176730A1 (en) 2009-07-09
KR20040094398A (ko) 2004-11-09

Similar Documents

Publication Publication Date Title
BR0214944A (pt) Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
DE60105424D1 (de) Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
BR9710355A (pt) Composição útil para o tratamento de infecções virais em um mamìfero, processo para tratar uma infecção viral em um mamìfero, e, produto medicinal.
BR0316407A (pt) Derivados de nucleosìdeo antiviral
WO2003026589A3 (en) Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
BR0110023A (pt) Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
MXPA04012779A (es) Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
BR0207752A (pt) Composto, sais de sódio, cálcio, potássio, magnésio, colina, etanolamina e trietilamina dos compostos, formas dos mesmos, métodos de tratamento ou de prevenção de uma infeção viral em um ser humano e de tratamento dos vìrus mutantes hiv uso de um composto, composição farmacêutica, e, processo para a preparação dos compostos
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
BR9707535A (pt) Utilização de uma quantidade farmacologicamente aceitável e terapeuticamente eficaz de um agente leucotrieno b4 (ltb4) e composição farmacêutica.
DK92788A (da) Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
MX9301922A (es) Composiciones para el tratamiento de infeccion y enfermedad ocasionadas por el virus de hepatitis b (hbv).
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
BG100835A (bg) Ново лекарствено средство за лечение на вирусни инфекции на дихателните пътища
WO2004013298A3 (en) 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
DK1143976T3 (da) Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner
BR0207931A (pt) Anticorpos naturais ativos contra vìrus hiv
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
WO1998001144A2 (en) Antiviral agents from plant extracts and use for treatment of viral infections
UA31078A (uk) Інгібітор вірусу імунодефіциту людини ( даримід )

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/513; C07D 239/47; A61P 31/18; A61P 31/22

Ipc: A61K 31/513 (2011.01), C07D 239/47 (2011.01), A61P

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.